Cassava Sciences Inc. Announces New Clinical Study for Simufilam as Potential Treatment for TSC-Related Epilepsy

Reuters

05-01

<a href="https://laohu8.com/S/SAVA">Cassava Sciences Inc</a>. Announces New Clinical Study for Simufilam as Potential Treatment for TSC-Related Epilepsy

Cassava Sciences Inc., a clinical-stage biotechnology company, has announced the appointment of Dr. Angélique Bordey as Senior Vice President, Neuroscience, to enhance its preclinical program in TSC-related epilepsy. Dr. Bordey, who will continue her academic role at Yale School of Medicine, will lead the scientific evaluation of simufilam, a potential novel treatment for this challenging epilepsy syndrome. Her expertise is expected to advance Cassava's research and development efforts, following a recent patent and license agreement with Yale University. This initiative marks a significant step in exploring new treatment options for TSC-related epilepsy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442729-en) on May 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2532075088"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532075088\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2532075088?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-01 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532075088","market":"us","top_or_hot":-1,"title":"Cassava Sciences Inc. Announces New Clinical Study for Simufilam as Potential Treatment for TSC-Related Epilepsy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a>. Announces New Clinical Study for Simufilam as Potential Treatment for TSC-Related Epilepsy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cassava Sciences Inc., a clinical-stage biotechnology company, has announced the appointment of Dr. Angélique Bordey as Senior Vice President, Neuroscience, to enhance its preclinical program in TSC-related epilepsy. Dr. Bordey, who will continue her academic role at Yale School of Medicine, will lead the scientific evaluation of simufilam, a potential novel treatment for this challenging epilepsy syndrome. Her expertise is expected to advance Cassava's research and development efforts, following a recent patent and license agreement with Yale University. This initiative marks a significant step in exploring new treatment options for TSC-related epilepsy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442729-en) on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cassava Sciences Inc. Announces New Clinical Study for Simufilam as Potential Treatment for TSC-Related Epilepsy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCassava Sciences Inc. Announces New Clinical Study for Simufilam as Potential Treatment for TSC-Related Epilepsy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-01 19:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a>. Announces New Clinical Study for Simufilam as Potential Treatment for TSC-Related Epilepsy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cassava Sciences Inc., a clinical-stage biotechnology company, has announced the appointment of Dr. Angélique Bordey as Senior Vice President, Neuroscience, to enhance its preclinical program in TSC-related epilepsy. Dr. Bordey, who will continue her academic role at Yale School of Medicine, will lead the scientific evaluation of simufilam, a potential novel treatment for this challenging epilepsy syndrome. Her expertise is expected to advance Cassava's research and development efforts, following a recent patent and license agreement with Yale University. This initiative marks a significant step in exploring new treatment options for TSC-related epilepsy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442729-en) on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAVA","symbol_name":"Cassava Sciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL4JzSmV:1","article_id":"2532075088","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532075088","pubTimestamp":1746099035,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cassava Sciences Inc., a clinical-stage biotechnology company, has announced the appointment of Dr. Angélique Bordey as Senior Vice President, Neuroscience, to enhance its preclinical program in TSC-related epilepsy. Dr. Bordey, who will continue her academic role at Yale School of Medicine, will lead the scientific evaluation of simufilam, a potential novel treatment for this challenging epilepsy syndrome. Her expertise is expected to advance Cassava's research and development efforts, following a recent patent and license agreement with Yale University. This initiative marks a significant step in exploring new treatment options for TSC-related epilepsy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published th","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SAVA":"Cassava Sciences Inc","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Cassava Sciences Inc.宣布Simufilam作为TSC相关癫痫潜在治疗方法的新临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SAVA":0.9},"content_text":"Cassava Sciences Inc. Announces New Clinical Study for Simufilam as Potential Treatment for TSC-Related Epilepsy\n    \n\n        Cassava Sciences Inc., a clinical-stage biotechnology company, has announced the appointment of Dr. Angélique Bordey as Senior Vice President, Neuroscience, to enhance its preclinical program in TSC-related epilepsy. Dr. Bordey, who will continue her academic role at Yale School of Medicine, will lead the scientific evaluation of simufilam, a potential novel treatment for this challenging epilepsy syndrome. Her expertise is expected to advance Cassava's research and development efforts, following a recent patent and license agreement with Yale University. This initiative marks a significant step in exploring new treatment options for TSC-related epilepsy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442729-en) on May 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}